Collin Gage, Author at PsyNews.com

Home Authors Posts by Watertime

426 POSTS 0 COMMENTS

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

1...41 4243Page 43 of 43

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

EDITOR PICKS

ShroomskiCon 2026

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY